LSTM Home > LSTM Research > LSTM Online Archive

A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease

Hansen, Richard, Sanderson, Ian R., Muhammed, Rafeeq, Allen, Stephen ORCID:, Tzivinikos, Christos, Henderson, Paul, Gervais, Lisa, Jeffery, Ian B., Mullins, David P., O'Herlihy, Eileen A., Weinberg, John D., Kitson, Geoff, Russell, Richard K. and Wilson, David C. (2021) 'A Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability of (Thetanix) Bacteroides thetaiotaomicron in Adolescent Crohn's Disease'. Clinical and Translational Gastroenterology, Vol 12, Issue 1, e00287.

Hansen 2020.pdf - Published Version
Available under License Creative Commons Attribution.

Download (431kB) | Preview
[img] Text
CTG-20-0421 rev clean_submitted.docx - Submitted Version
Restricted to Repository staff only

Download (114kB)
[img] Text
CTG-20-0421 Supplementary rev clean_submitted.docx - Supplemental Material
Restricted to Repository staff only

Download (74kB)


Thetanix (gastroresistant capsules containing lyophilized Bacteroides thetaiotaomicron) is a live biotherapeutic, under development for Crohn's disease, that antagonizes transcription factor nuclear factor kappa B, reducing proinflammatory cytokines, particularly tumor necrosis factor alpha. We aimed to assess safety and tolerability in adolescents with Crohn's disease in remission.

Subjects who were 16–18 years with Crohn's in remission (weighted pediatric Crohn's disease activity index <12.5) were recruited. Each active dose comprised ∼108.2±1.4 colony forming units of B. thetaiotaomicron (randomized 4:1 active:placebo). Part A was single dose. Part B involved 7.5 days twice daily dosing. Serial stools were analyzed for calprotectin, 16S rRNA sequencing, and B. thetaiotaomicron real-time polymerase chain reaction. Bloods were taken serially. Subjects reported adverse events and recorded temperature twice daily.

Fifteen subjects were treated—8 in part A (75% men, median 17.1 years) and 10 in part B, including 3 from part A (80% men, median 17.1 years); all 18 completed. Seventy percent took concurrent immunosuppression. Reported compliance was >99% in part B. Two subjects reported adverse events deemed related—one in part A with eructation, flatulence, and reflux; one in part B with dizziness, abdominal pain, and headache. No serious adverse events were reported. There was no significant change in median calprotectin across part B (87.8 [4.4–447] to 50.5 [5.3–572], P = 0.44 by the Fisher exact test in the active group). No significant differences were found in microbiota profiles, but diversity seemed to increase in treated subjects.

Thetanix, after single and multiple doses, was well tolerated. Although the numbers in this study were small, the safety profile seems good. Future studies should explore efficacy.

Item Type: Article
Subjects: QW Microbiology and Immunology > QW 50 Bacteria (General). Bacteriology. Archaea
WI Digestive System > WI 100 General works
WI Digestive System > WI 140 Diseases (General)
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):
Depositing User: Marie Hatton
Date Deposited: 04 Jan 2021 15:25
Last Modified: 04 Jan 2021 15:25


View details

Actions (login required)

Edit Item Edit Item